Circassia Pharmaceuticals’ (CIR) Buy Rating Reiterated at Numis Securities

Circassia Pharmaceuticals (LON:CIR)‘s stock had its “buy” rating reaffirmed by investment analysts at Numis Securities in a report issued on Monday, April 1st, LSE.Co.UK reports. They currently have a GBX 110 ($1.44) price target on the stock. Numis Securities’ price objective points to a potential upside of 270.37% from the company’s previous close.

Several other brokerages have also commented on CIR. Peel Hunt reaffirmed a “buy” rating on shares of Circassia Pharmaceuticals in a research report on Thursday, December 6th. Royal Bank of Canada reduced their price target on shares of Circassia Pharmaceuticals from GBX 81 ($1.06) to GBX 65 ($0.85) and set a “sector performer” rating for the company in a research report on Thursday, January 24th.

Shares of LON:CIR traded up GBX 0.25 ($0.00) during trading on Monday, reaching GBX 29.70 ($0.39). The stock had a trading volume of 110,447 shares. The stock has a market capitalization of $111.16 million and a P/E ratio of -1.12. Circassia Pharmaceuticals has a one year low of GBX 25 ($0.33) and a one year high of GBX 98.30 ($1.28).

Circassia Pharmaceuticals Company Profile

Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD).

Featured Article: What is the Rule of 72?

Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.